CureMeAbroad
AI-powered cross-border healthcare platform for discovering, comparing, and booking international medical treatments.
Website: https://curemeabroad.com
Cover Block
Public sources
| Field | Value |
|---|---|
| Name | CureMeAbroad |
| Tagline | AI-powered cross-border healthcare platform for discovering, comparing, and booking international medical treatments. |
| Headquarters | Pune, India [Hindustan Times, March 2026] |
| Founded | 2025 [Economic Times Startup, April 2026] |
| Stage | Pre-Seed [Digital Health News, October 2026] |
| Business model | Marketplace |
| Industry | Healthtech |
| Technology | AI / Machine Learning [Economic Times Startup, April 2026] |
| Geography | South Asia |
| Growth profile | Venture Scale |
| Founding team | Aditya Oza and Mikhail Bohra [Digital Health News, October 2026] |
| Funding label | Pre-seed |
| Total disclosed funding | Approximately $1.7 million across two pre-seed rounds [Economic Times Startup, April 2026] [Digital Health News, October 2026] |
Links
Public sources
- Website: https://curemeabroad.com/about-us
Executive Summary
PUBLIC CureMeAbroad is a Pune-based marketplace for cross-border healthcare that aims to make international treatment discovery, comparison, and booking more legible for patients, and it merits investor attention because it has moved from launch in 2025 to two pre-seed financings totaling about $1.7 million by October 2026, alongside an expanding hospital network claim across multiple destinations [Digital Health News, October 2026] [Economic Times Startup, April 2026] [Economic Times Entrepreneur, April 2026]. The founding story is still early, but public coverage consistently identifies the company as founded by Aditya Oza and Mikhail Bohra, with Oza serving as CEO and Bohra as CMO; a March 2026 local profile adds that the two are cousins and launched the business from Pune [Digital Health News, October 2026] [Express Healthcare, October 2026] [Hindustan Times, March 2026].
The product proposition is straightforward: CureMeAbroad connects international patients with hospitals, surgeons, and treatment destinations, then layers on provider verification, hospital comparison, AI-based clinical matching, treatment-cost estimates, and booking support [Economic Times Startup, April 2026] [Economic Times Entrepreneur, April 2026]. The differentiation, to the extent public evidence supports it, rests less on a novel care-delivery model than on reducing the usual fragmentation in medical tourism, especially around provider credibility, pricing visibility, and coordination across borders [Economic Times Startup, April 2026] [Express Healthcare, October 2026].
On team quality, the public record is mixed but directionally constructive. Oza has at least one prior founding credit through EMotorad, which TechCrunch identified in 2023 as an India-based e-bike company he co-founded, while public reporting on Bohra is thinner and centers mainly on his operating role at CureMeAbroad [TechCrunch, November 2023] [Express Healthcare, October 2026].
The financing picture is clearer than the operating picture. CureMeAbroad raised $600,000 in April 2026 from a group of angels that included Roman Saini, Himanshu Ratnoo, Kunal Gupta, Devaiah Bopanna, Vikrant Potnis, and AIRA Buildon, then added a $1.1 million pre-seed round in October 2026 led by SteerX Ventures with AIRA participating, which gives the company a disclosed funding base consistent with an asset-light marketplace buildout [Economic Times Startup, April 2026] [Financial Express, April 2026] [Digital Health News, October 2026].
Over the next 12 to 18 months, the main points to watch are whether the company can convert network breadth into repeatable patient flow, whether its reported hospital footprint stabilizes around one verifiable figure, and whether company-reported revenue claims begin to show up in more independently corroborated form [Economic Times Entrepreneur, April 2026] [entrackr.com] [Hindustan Times, March 2026]. The setup is promising, but the central diligence question remains execution quality in a trust-sensitive category where marketplace supply, accreditation standards, and care coordination all need to hold up under scale.
Lightly corroborated -- This section relies primarily on named-publication funding and profile coverage, with several operating metrics still resting on company statements or single-source reporting.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | Marketplace |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | South Asia |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | ~$1.7M disclosed |
How the Company Got Here
PUBLIC
CureMeAbroad appears to be very early, but the basic company shape is clear from public company profiles. Crunchbase identifies it as a Pune-based healthtech marketplace founded in 2025, focused on cross-border healthcare discovery and booking [Crunchbase]. The company website presents the same operating concept in plain terms, positioning the platform around helping patients compare international treatment options and make verified provider choices [CureMeAbroad.com].
The public record is thin on formal entity detail, and no state filing was provided in the source set, so the cleaner approach is to stay with what is corroborated. On chronology, the confirmed milestones begin with the 2025 founding date on Crunchbase, followed by the company website's public positioning around international care navigation and provider comparison [Crunchbase] [CureMeAbroad.com]. Those sources support headquarters, category, and founding year, but not a more developed legal or operating history.
Lightly corroborated -- Confirmed with two public company-profile sources for founding year, headquarters, and business focus, but no state filing or legal-entity record was provided in the source set.
Product and Technology
MIXED
The product pitch is narrower than the category often suggests. CureMeAbroad presents itself as a cross-border care platform for discovering, comparing, and booking treatment with international hospitals and specialists, with the workflow centered on provider verification, treatment-cost estimation, and booking support rather than a generic hospital directory alone [Economic Times Startup, April 2026] [Economic Times Entrepreneur, April 2026]. Public coverage also describes an AI-based clinical matching layer and comparison tooling, alongside verification against JCI or equivalent national accreditation standards, which points to a consumer-facing decision-support product built around trust and coordination in a high-friction purchase [Economic Times Startup, April 2026] [ETEntrepreneur].
The available evidence suggests two product surfaces, and the distinction matters. One is a broad discovery layer: multiple outlets report a directory of more than 6,000 hospitals across 47 countries, while separate coverage describes an active network of more than 380 hospitals, later more than 400 accredited hospitals, across a smaller set of operating markets [startupfox.in] [Travel And Tour World] [Economic Times Entrepreneur, April 2026] [entrackr.com]. Read conservatively, that implies a large searchable supply base and a narrower transactable or curated network, although the company has not publicly broken out how many providers are bookable versus listed. Press reports also show the platform extending into specific treatment journeys, including support throughout care coordination and named MoUs with Asia Cosmetics and Dr Brenda’s Clinic for aesthetic procedures, which indicates the product is not purely lead generation at this stage [ETEntrepreneur] [Express Healthcare, July 2026].
What is still missing from the public record is as useful as what is present. There is no verified public demo, no disclosed technical architecture, and no direct evidence on whether the AI layer is proprietary, rules-based, or built on third-party models; any harder claim on stack would outrun the sourcing. For investors, the core product question is less whether the interface exists, which press coverage supports, and more whether CureMeAbroad can convert verification, pricing transparency, and booking assistance into a repeatable marketplace experience across geographies where care quality, accreditation norms, and patient expectations vary materially [Economic Times Startup, April 2026] [Express Healthcare, October 2026].
Lightly corroborated -- Product scope is corroborated across Economic Times Startup and Economic Times Entrepreneur, but the deeper operating distinctions between directory, network, and transactable supply remain only partially verified in public sources.
Where the Demand Sits
Public sources
Cross-border healthcare is drawing capital because the gap between local treatment access and globally available capacity remains real, but the public record here is thinner on category sizing than on company positioning [Economic Times Startup, April 2026] [Express Healthcare, October 2026]. For CureMeAbroad, that means the market case has to be built from observable demand signals rather than a clean third-party TAM model. The available coverage consistently describes a product aimed at reducing friction in provider selection, pricing transparency, and care coordination for patients traveling abroad, which is a recognizable pain point in medical tourism and broader patient-navigation markets [Economic Times Startup, April 2026] [Economic Times Entrepreneur, April 2026].
The TAM, SAM, and SOM remain unquantified in the cited record, so any sizing discussion has to stay narrow. What is confirmed publicly is that CureMeAbroad has framed its reachable supply base around a directory of more than 6,000 hospitals across 47 countries in some coverage, while separate reporting described an active network of more than 380 hospitals across India, Mexico, Turkey, Thailand, and Georgia in April 2026, later expanding to more than 400 accredited hospitals across six countries in other coverage [startupfox.in] [Travel And Tour World] [Economic Times Entrepreneur, April 2026] [entrackr.com]. That spread suggests two adjacent market layers: a broad discovery market, where users compare destinations and providers at the top of funnel, and a narrower transaction market, where vetted hospital relationships and booking support matter more than directory breadth [Economic Times Startup, April 2026] [ETEntrepreneur].
| Cited market proxy | Reported scope | What it indicates |
|---|---|---|
| CureMeAbroad directory footprint | More than 6,000 hospitals across 47 countries [startupfox.in] | Broad discovery layer, useful for top-of-funnel patient search |
| CureMeAbroad active network | More than 380 hospitals across India, Mexico, Turkey, Thailand, and Georgia [Economic Times Entrepreneur, April 2026] | Narrower operating footprint tied to destinations the company appears to support directly |
| Later network description | More than 400 accredited hospitals across six countries [entrackr.com] | Some reported expansion, though the chronology and exact country mix need corroboration |
| Specialty coverage | 45 medical specialties [Travel And Tour World] | Demand may span elective and complex procedures rather than a single treatment vertical |
The picture that emerges is less about a single monolithic market size and more about a funnel conversion problem. The larger directory claims imply broad user intent capture, while the smaller verified network figures likely sit closer to actual service delivery. That distinction matters because marketplaces in cross-border care tend to monetize the latter, not the former.
Demand drivers in the public coverage are clearer than market size. Multiple reports say the platform connects international patients with hospitals, surgeons, and treatment destinations, and emphasizes verification, cost estimates, and booking support, all functions that become more valuable when patients are comparing care options across borders without local trust networks [Economic Times Entrepreneur, April 2026] [Economic Times Startup, April 2026] [Express Healthcare, October 2026]. The company has also been associated with inquiry flow in cosmetic and aesthetic procedures through July 2026 partnership coverage, which points to one practical tailwind: elective treatments are often more price-transparent, more portable, and less dependent on long local referral chains than acute care [Express Healthcare, July 2026].
There are also supply-side signals. Coverage of memoranda with Asia Cosmetics and Dr Brenda's Clinic, plus reported network expansion into Thailand, Turkey, and Mexico, suggests that providers in established treatment destinations see value in structured international patient acquisition rather than informal broker channels alone [Express Healthcare, July 2026]. That aligns with CureMeAbroad's stated pitch around verified facts and accreditation-based provider screening, including checks against JCI or equivalent national accreditation, according to cited reports [Travel And Tour World] [ETEntrepreneur].
The adjacent markets are important because they shape both upside and substitution risk. At one edge, this looks like medical tourism distribution, where the customer is shopping for a destination, a provider, and an estimated price in one flow [Economic Times Entrepreneur, April 2026]. At another, it overlaps with digital patient navigation and healthcare marketplace software, especially where the product's AI-supported matching and treatment-cost estimation sit upstream of booking [Economic Times Startup, April 2026]. A third adjacency is concierge care for elective procedures, particularly cosmetic and aesthetic treatments, where cross-border travel can be planned in advance and provider differentiation is easier to present digitally [Express Healthcare, July 2026].
Those adjacencies cut both ways. They expand the possible revenue surface, but they also mean CureMeAbroad is not competing only with medical-tourism facilitators. Patients can default to domestic second-opinion platforms, hospital international desks, referral networks, insurers, or destination-specific facilitators depending on procedure type and geography. In practical terms, the market is likely segmented first by treatment category and patient urgency, then by destination trust and price sensitivity.
Regulatory and macro forces remain material even if the sources do not map them in detail. Cross-border healthcare depends on visa regimes, accreditation standards, patient-data handling, payment flows, and post-treatment continuity, all of which can slow conversion even when demand exists. The public record gives two modest trust markers: CureMeAbroad was reported as a United Nations Global Compact signatory in July 2026, and it received Medical Travel Facilitator Certification from Global Healthcare Accreditation in separate coverage [Express Healthcare, July 2026] [entrackr.com]. Neither solves regulatory complexity by itself, but both speak to a market where trust infrastructure is part of the product, not a marketing layer.
Macro conditions appear supportive in a narrow sense. Patients in high-cost markets continue to search for lower-cost or faster-access alternatives, while hospitals in destination countries have incentives to attract international demand that improves utilization and mix. The public sources stop short of quantifying those flows, so the cautious read is that the category has visible demand and clear buyer pain, but the investable question turns on execution quality inside specific treatment corridors rather than on a proven, publicly benchmarked market-size narrative [Hindustan Times, March 2026] [Economic Times Startup, April 2026].
Single unverified source -- This section relies on named public coverage for product positioning and network scope, but it lacks independent third-party market-sizing reports and includes some company-linked or single-source market proxies [Economic Times Entrepreneur, April 2026] [Economic Times Startup, April 2026] [entrackr.com] [Travel And Tour World] [startupfox.in].
Competitive Landscape
MIXED CureMeAbroad is positioning itself less as a generic medical tourism lead generator and more as a verification and booking layer for cross-border care, which places it between broad hospital directories and higher-touch facilitation services [Economic Times Startup, April 2026] [Economic Times Entrepreneur, April 2026].
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| CureMeAbroad | AI-powered cross-border healthcare platform for discovering, comparing, and booking international medical treatments | Pre-seed, $1.7M disclosed across two rounds | Reported focus on provider verification, AI-based clinical matching, treatment-cost estimates, and booking support | [Digital Health News, October 2026] [Economic Times Startup, April 2026] |
| Bookimed | Medical tourism marketplace connecting patients with clinics across countries | Not established from provided public sources | Named competitor in structured research | [Structured Facts] |
| PlacidWay | Medical tourism platform connecting patients with treatment providers internationally | Not established from provided public sources | Named competitor in structured research | [Structured Facts] |
| The Medical Tourism Company | Medical travel facilitator | Not established from provided public sources | Named competitor in structured research | [Structured Facts] |
| Medical Departures | Marketplace for booking dental and cosmetic treatment abroad | Not established from provided public sources | Named competitor in structured research | [Structured Facts] |
The map breaks into three practical segments. Third are adjacent substitutes, chiefly direct hospital international desks and offline referral agents, the latter being the workflow CureMeAbroad has explicitly said it wants to replace with verified information and structured comparison [Travel And Tour World].
CureMeAbroad's edge, on the public record, is narrow but legible. Multiple reports describe a product stack that combines provider verification, accreditation checks, AI-supported matching, cost estimation, and booking support, rather than stopping at provider discovery [Economic Times Startup, April 2026] [Economic Times Entrepreneur, April 2026] [ETEntrepreneur]. That is useful if international patients are comparing not just destinations but trust signals. The difficulty is durability. Verification workflows and estimator interfaces can differentiate a young marketplace early, but they are perishable unless they compound into proprietary conversion data, repeat hospital-side demand, or a brand patients seek out directly. The disclosed hospital network, reported at more than 380 hospitals in April 2026 and more than 400 accredited hospitals in later coverage, suggests some early supply aggregation, though the exact overlap between directory listings and active commercial relationships is not clear from public sources [Economic Times Entrepreneur, April 2026] [entrackr.com].
The main exposure is channel control. CureMeAbroad also does not appear, from the available reporting, to own a captive referral channel such as insurer distribution, employer benefits, or hospital-system exclusivity. That leaves it competing for patient trust and provider onboarding at the same time, which is expensive work for a company still at pre-seed scale [Digital Health News, October 2026] [Express Healthcare, October 2026].
The most plausible 18-month scenario is a split market. CureMeAbroad is the likely winner if the category tilts toward verified matching, accreditation-led trust, and high-consideration procedures where patients want more decision support than a listing site can offer [Economic Times Startup, April 2026] [ETEntrepreneur]. The clearest loser if offline agents remain opaque and hospitals push patients toward direct intake is any platform, including CureMeAbroad, that cannot convert verification into owned demand rather than acting as a thin intermediary [Travel And Tour World] [Express Healthcare, October 2026].
Single unverified source -- Subject-company positioning and funding are supported by named public outlets, but competitor detail is limited to structured research and several category comparisons remain only partially corroborated.
Opportunity
Upside case
Public sources If CureMeAbroad executes unusually well, the prize is not a niche lead-generation business but a trusted cross-border care marketplace that sits between global patients and accredited providers, and captures the high-intent traffic now handled through fragmented brokers, direct hospital marketing, and manual referral channels [Economic Times Startup, April 2026] [Economic Times Entrepreneur, April 2026].
The clearest upside path is becoming a default transaction and discovery layer for international treatment selection, especially in corridors where price transparency, provider verification, and care coordination remain uneven. That outcome is still early, but it is not purely aspirational on the public record. By April 2026, the company was reported to offer provider verification, hospital comparison, AI-based clinical matching, treatment-cost estimates, and booking support, with a network of more than 380 hospitals across India, Mexico, Turkey, Thailand, and Georgia [Economic Times Startup, April 2026] [Economic Times Entrepreneur, April 2026]. By October 2026, it had added a $1.1 million pre-seed round led by SteerX Ventures after an earlier $600,000 pre-seed financing, which suggests outside investors see room to scale supply, patient acquisition, and product depth rather than treating the platform as a small service business [Digital Health News, October 2026] [Financial Express, April 2026].
The opportunity is attractive because the platform appears to be trying to own the decision layer, not just the booking moment. In cross-border healthcare, the hardest problem is often not discovery alone but confidence: which hospital is accredited, what the likely treatment pathway is, what the cost range looks like, and whether support continues after the booking. CureMeAbroad's public positioning is built around those frictions, and that gives it a plausible route to higher-value economics if patients and providers begin to treat the platform as a trusted gatekeeper rather than a referral source [Economic Times Startup, April 2026] [ETEntrepreneur].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Verified corridor leader | CureMeAbroad becomes a leading marketplace for a defined set of outbound treatment corridors, aggregating accredited hospitals and concentrating patient demand in categories where price comparison matters most. | Expansion of the hospital network across India, Mexico, Turkey, Thailand, and Georgia, combined with more visible proof of accreditation-based matching [Economic Times Entrepreneur, April 2026] [entrackr.com]. | The company already reports a multi-country network and verification workflow, which fits categories where trust and comparison are the core purchase drivers [Economic Times Startup, April 2026]. |
| Specialist care aggregator | The platform wins in a narrower but high-intent segment such as cosmetic and elective procedures, then broadens into adjacent specialties with repeatable playbooks. | Partnerships such as the July 2026 MoUs with Asia Cosmetics and Dr Brenda's Clinic create supply density in one procedure family [Express Healthcare, July 2026]. | Public coverage says aesthetic procedures are a major enquiry category, which supports the idea that a focused wedge could produce better conversion than a broad directory alone [Express Healthcare, July 2026]. |
| Trust infrastructure for medical travel | CureMeAbroad evolves from marketplace into the preferred verification and patient-navigation layer used by hospitals and facilitators across regions. | Its Medical Travel Facilitator Certification from Global Healthcare Accreditation and UN Global Compact signatory status improve institutional credibility with providers and patients [entrackr.com] [Express Healthcare, July 2026]. | In markets with fragmented intermediaries, trust markers can matter disproportionately. The company's public messaging is already centered on replacing unverified agent networks with documented provider information and booking support [Travel And Tour World] [ETEntrepreneur]. |
The compounding mechanism, if it appears, is straightforward. More hospitals create more choice and better price discovery, which should improve patient conversion; more patient demand gives the platform stronger negotiating use with providers and better signal on which specialties and destinations convert; that data can then sharpen matching, cost estimates, and ranking quality over time [Economic Times Startup, April 2026] [Economic Times Entrepreneur, April 2026]. Even the current public footprint hints at the first stage of that loop: the company has been reported with a 380-plus hospital network in April 2026 and a 400-plus accredited hospital network in later coverage, while also adding targeted clinic partnerships in aesthetics [Economic Times Entrepreneur, April 2026] [entrackr.com] [Express Healthcare, July 2026].
A second layer of compounding could come from trust accumulation. In cross-border care, each successful navigation outcome can lower the perceived risk for the next patient, particularly when treatment is expensive or emotionally high-stakes. Publicly reported markers such as accreditation verification, facilitator certification, and named provider partnerships do not prove category leadership, but they do support the view that the company is trying to build a repeatable trust architecture rather than compete only on search traffic [ETEntrepreneur] [entrackr.com] [Express Healthcare, July 2026].
The size of the win is harder to anchor precisely because no credible market-size source is included in the current record. Even so, there is a reasonable scenario frame. If CureMeAbroad were to become one of the few scaled, trusted platforms for cross-border patient flow across several destination countries, a strategic outcome could resemble a valuable healthcare-commerce asset rather than a small travel-services intermediary. The company reported a $2.4 million annualized run rate in March 2026, though that figure is company-reported and should be treated cautiously [Hindustan Times, March 2026]. If a future version of the business reached, for example, 20 times that run rate through corridor expansion, higher take rates, and deeper specialty penetration, it would imply roughly $48 million in annualized revenue (estimated) based on 20 x $2.4 million [Hindustan Times, March 2026]. At that scale, the business could plausibly support a venture outcome in the low hundreds of millions of dollars in enterprise value (scenario, not a forecast), assuming marketplace-quality growth and defensibility. That is an inference, not an observed market benchmark, but it captures the basic point: the upside case is meaningful if the company becomes the trust layer for medical travel, not merely a listing site.
Single unverified source -- Core product, geography, funding, and network claims are supported by named public coverage including Economic Times, Financial Express, Digital Health News, and Express Healthcare. The section's upside framing and value range rely partly on inference, and the only revenue anchor cited here is company-reported in Hindustan Times.
Sources
Public sources
[Hindustan Times, March 2026] Connecting patients to care without borders | https://www.hindustantimes.com/cities/pune-news/connecting-patients-to-care-without-borders-101774637315868.html
[Economic Times Startup, April 2026] Curemeabroad secures 600k pre seed funding to rework medical tourism | https://startup.economictimes.indiatimes.com/news/funding-deals/curemeabroad-secures-600k-pre-seed-funding-to-rework-medical-tourism/130442881
[Digital Health News, October 2026] CureMeAbroad Raises $1.1 Mn in Pre-Seed Round Led by SteerX Ventures | https://www.digitalhealthnews.com/curemeabroad-raises-1-1-mn-in-pre-seed-round-led-by-steerx-ventures
[Economic Times Entrepreneur, April 2026] CureMeAbroad bags $600,000 pre-seed funding led by angel investors | https://entrepreneur.economictimes.indiatimes.com/news/funding/curemeabroad-secures-600000-in-pre-seed-funding-to-transform-medical-tourism/130419503
[Express Healthcare, October 2026] CureMeAbroad raises $1.1 Mn in pre-seed round led by SteerX Ventures, AIRA Doubles Down | https://www.expresshealthcare.in/amp/news/curemeabroad-raises-1-1-mn-in-pre-seed-round-led-by-steerx-ventures-aira-doubles-down/455437/
[TechCrunch, November 2023] India's EMotorad rides high with $20M investment for global e-bike push | https://techcrunch.com/2023/11/26/india-emotorad-funding-series-b-ebike/
[Financial Express, April 2026] CureMeAbroad raises $ 600000 in pre-seed round | https://www.financialexpress.com/business/start-ups/curemeabroad-raises-600000-in-pre-seed-round-startup-aiming-to-simplify-medical-tourism-gets-backing-from-roman-saini/4214478/
[Crunchbase] CureMeAbroad - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/curemeabroad
[CureMeAbroad.com] About Us - CureMeAbroad.com | Empowering Global Healthcare Choices | https://curemeabroad.com/about-us
[Express Healthcare, July 2026] CureMeAbroad signs MoUs with Asia Cosmetics and Dr Brenda’s Clinic | https://www.expresshealthcare.in/amp/news/curemeabroad-signs-mous-with-asia-cosmetics-and-dr-brendas-clinic/454537/
Articles about CureMeAbroad
- CureMeAbroad's AI Platform Maps 400 Hospitals for Cross-Border Patients — The Pune-based startup is building a marketplace to simplify access to international treatment, backed by investors from Unacademy and EMotorad.